Cognition Therapeutics, Inc.
NASDAQ:CGTX
Overview | Financials
Company Name | Cognition Therapeutics, Inc. |
Symbol | CGTX |
Currency | USD |
Price | 0.474 |
Market Cap | 19,039,076 |
Dividend Yield | 0% |
52-week-range | 0.34 - 2.95 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Ms. Lisa Ricciardi |
Website | https://www.cogrx.com |
An error occurred while fetching data.
About Cognition Therapeutics, Inc.
Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, a sigma-2 receptor antagonist, which is in Phase II clinical trial for the treatment
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD